1. Scrip
  2. >>Archive

Best of the Blog START-UP February 2009

 
• By Tom Salemi

A selection of our best blog posts from February for stories not covered elsewhere in the magazine includes: Friends in High Places: The White House appears to appreciate the need for innovation and, Medtronic's $1.03 billion buying spree is only the beginning in percutaneous heart valves.

Best of the Blog is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In February Windhover’s editorial staff posted 40 articles to the site, covering biopharma, device and diagnostics R&D, business development, regulatory, and commercial news. Highlights included the first in our new and ongoing series of Podcasts, continued prognostication about Obama Administration appointments and health reform, and top-notch and timely coverage of the biggest industry deals. Here are a few of our favorite blog posts and excerpts for stories not covered elsewhere in this month’s START-UP.

(February 5.) VCs finally seem to have a friend residing in the White House. The Venture Capital Journal declared so in its cover story.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.